Document Detail


Prevention of chemotherapy-induced leukemia and of leukemia relapses.
MedLine Citation:
PMID:  1725055     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Fifty percent of patients with the myelodysplastic syndrome, frequently following treatment by radiation or chemotherapy, have prognostically unfavorable deletions of the long arms of chromosomes 5 and 7, or trisomy 8, as have the 25% of patients with acute myeloblastic leukemia where remissions last 6-12 months, and where relapse cannot be prevented. In contrast, patients with prognostically favorable cytogenetics (translocation 15; 17 or 8; 21 or inversion 16) maintenance chemotherapy may prevent relapses. Of chronic myelocytic leukemia patients, 85% can achieve hematological remission with interferon alpha, and 40% a partial cytogenetic remission, which probably delays relapse.
Authors:
E J Freireich
Related Documents :
22927525 - Phase ii trial of cetuximab with or without paclitaxel in patients with advanced urothe...
23897955 - Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era:...
10194135 - B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prog...
24252855 - Accuracy and prognostic value of sentinel lymph node biopsy in head and neck melanomas.
1847795 - The potential role of postoperative hepatic artery chemotherapy in patients with high-r...
10522005 - Analysis of macroscopic appearance and p53 expression in superficial esophageal carcinoma.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Medical oncology and tumor pharmacotherapy     Volume:  8     ISSN:  0736-0118     ISO Abbreviation:  Med Oncol Tumor Pharmacother     Publication Date:  1991  
Date Detail:
Created Date:  1992-04-30     Completed Date:  1992-04-30     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8405039     Medline TA:  Med Oncol Tumor Pharmacother     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  155-8     Citation Subset:  IM    
Affiliation:
Adult Leukemia Research Program, University of Texas, M.D. Anderson Cancer Center, Houston 77030.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / adverse effects*
Humans
Interferons / therapeutic use
Leukemia / chemically induced,  prevention & control*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Recurrence
Remission Induction / methods
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 9008-11-1/Interferons

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Angiotensin-converting enzyme inhibitors in heart failure: a role after myocardial infarction.
Next Document:  Methods for field detection of resistance to temephos in simuliids. Larval esterase level and topica...